Abstract The novel siderophore cephalosporin cefiderocol (S-649266) with potent activity against Gram-negative pathogens was recently developed (Shionogi & Co., Ltd.). Here, we evaluated the activity of this new molecule and comparators against a collection of previously characterized Gram-negative isolates using broth microdilution panels. A total of 753 clinical multidrug-resistant Gram-negative isolates collected from hospitals worldwide were tested against cefiderocol and antibiotic comparators ( 
Introduction
Gram-negative bacteria that produce extended-spectrum β-lactamases (ESBLs) are a major concern in healthcare due to their ability to spread globally [1] . ESBLs are a major group of enzymes that confer resistance to several generations of β-lactam antibiotics, including third-generation cephalosporins [2, 3] . ESBL-encoding genes that are primarily plasmidencoded include mostly TEM-, SHV-, and CTX-M-type enzymes [4] . Enterobacteriaceae, such as Klebsiella pneumoniae and Escherichia coli, are the main ESBL producers that have been reported globally. Carbapenems are mostly used for the treatment of infections due to ESBL-producing bacteria, but carbapenemase-producing bacteria are now extensively reported [5, 6] . Polymyxins (e.g., colistin and polymyxin B) are now more frequently used as last-resort antibiotics for treating patients with multidrug-resistant bacterial infections [7] . However, a recent report shows that a novel gene (mcr-1) as a source of plasmid-encoded resistance encoded on a plasmid in E. coli may quickly spread to other bacterial strains or species [8] [9] [10] . Therefore, due to the increasing threat of multidrug-resistant and pandrug-resistant bacteria, there is a need for novel molecules. Cefiderocol (CFDC) is a novel parenteral siderophore cephalosporin also known as S-649266. It possesses a unique mechanism for penetrating efficiently into Gram-negative pathogens. It uses a BTrojan horse^strategy by binding free iron and is then actively transported into bacterial cells across the outer membrane of Gram-negative bacteria by way of the iron-transport system [11, 12] . Cefiderocol is a cephalosporin molecule with an attached catechol moiety on the 3-position side chain which binds to ferric iron [11] . Once across the outer membrane, the iron dissociates and the cephalosporin binds to penicillin-binding proteins (PBP), mainly PBP3, as other cephalosporins do to disrupt cell wall synthesis [11, 13] , contributing to a potent antimicrobial activity against Gram-negative bacteria. In addition, this antimicrobial activity of cefiderocol is enhanced by the high stability of cefiderocol to hydrolysis by nearly all β-lactamases, including both the serine and metallo-carbapenemases [14] . The ability to cross the outer membrane through the active iron-transport system overcomes resistance due to porin channel mutations and efflux pump overproducers. It results that cefiderocol exhibits potent in vitro and in vivo activity against all species of Gramnegative bacteria, including carbapenem-resistant strains of Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii, and even Stenotrophomonas maltophilia [15] . Here, we evaluated the antimicrobial activity of cefiderocol and other Gram-negative antibiotics (aztreonam, amikacin, cefepime, ceftazidime, ceftazidime-avibactam, ceftolozane-tazobactam, ciprofloxacin, meropenem, colistin, and tigecycline) against a panel of 753 multidrug-resistant bacterial isolates from human clinical sources with characterized antibiotic resistance mechanisms.
Materials and methods

Bacterial isolates
A total of 753 clinical multidrug-resistant isolates were evaluated in this study (Table 1) . They were representative of the most widespread and broad-spectrum mechanisms of resistance currently observed worldwide in Gram-negative bacteria. The strains were collected from hospitals worldwide (42 countries) from 2000 to 2016, with a majority dating from the 2012-2016 period. They were of various origins (not always recorded) but mostly from urines, broncho-alveolar specimens, blood, pus, and stools.
In vitro susceptibility test methods
Minimum inhibitory concentrations (MICs) were determined following the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BMD) guidelines [16] . Frozen 96-well broth microdilution panels with pre-loaded antibiotic-growth medium were supplied by International Health Management Associates, Inc. (Schaumburg, IL, USA). Cefiderocol was tested in iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) [17] , as recently approved by the CLSI (http://clsi.org/standards/micro/ microbiology-files/), whereas comparators were tested in cation-adjusted Mueller-Hinton broth (CAMHB). Quality The strains were grown overnight on a non-selective agar medium and two to three colonies were solubilized in 3 mL sterile 0.85% NaCl. The turbidity was adjusted to 0.5 McFarland with a McFarland densitometer DEN-1B from Grant Bio (Grant instruments Ltd., Cambridge, UK). One milliliter of inoculum was then diluted in 29 mL of sterile ddH 2 O and 10 μL were added to each BMD panel well. The panels were incubated for 16-20 h at 35°C. To ensure an even thermal distribution during incubation, the panels were stacked no more than four high. The MIC reading was then done according to the CLSI guidelines [18] .
Results and discussion
The susceptibility test results are listed in Tables 2-7 . The MIC 90 (MIC value that inhibits 90% of the isolates) of cefiderocol was 2 mg/L (Table 2) The MIC 50 and MIC 90 of CFDC for Enterobacteriaceae producing KPC carbapenemases were ≤1 μg/mL and ≤2 mg/ L, respectively ( Table 3 ). The only competitive comparators were ceftazidime-avibactam (MIC 50/90 ) (1/4), colistin (≤0.5/ OXA-48-like producing Enterobacteriaceae were susceptible to a larger number of antibiotics compared to the KPC producers (Table 4) . Again, cefiderocol is one of the antibiotics with the lowest MIC 50/90 values, at 0.25 and 2 μg/mL, respectively. Direct competitors were ceftazidime-avibactam (0.5/4), meropenem (1/32), amikacin (≤4/16), colistin (≤0.5/ 1), and tigecycline (≤0.5/≤1). Again, for Klebsiella sp., the MIC 90 of CZA and MEM were affected by outliers and the MIC 50 values should be considered instead.
For the enterobacterial isolates producing NDM, VIM, or IMP carbapenemases (Table 5 ), the only antibiotics that had strong activity (MIC 50/90 ) were cefiderocol (1/4), colistin (≤0.5/≤1), and tigecycline (≤0.25/≤1).
Colistin-resistant strains, mainly Enterobacteriaceae, had high susceptibility to cefiderocol (≤0.5/≤2) and some activity for ceftolozane-tazobactam in the case of E. coli (0.25/>64), ceftazidime-avibactam (0.5/>64), meropenem (0.12/64), amikacin (≤4/16), and tigecycline (≤1/≤1). Except for cefiderocol and tigecycline, the MIC 90 values were close to or above the upper limit of the concentration range of the tested antibiotics for the Enterobacteriaceae being resistant to colistin. This could be explained by additional resistance traits, such as expression of genes encoding carbapenemases and ESBLs, in particular for K. pneumoniae and Enterobacter sp. The level of resistance to colistin (MIC 90 = 2) and of meropenem (MIC 90 = 1) was lower for E. coli than that noted for K. pneumoniae and Enterobacter sp.
Carbapenemase-producing P. aeruginosa were susceptible only to cefiderocol (0.5/2) and colistin (≤0.5/1) ( Table 6 ). The same resistance trend was observed for carbapenemaseproducing A. baumannii strains [CFDC (0.12/4) and CST (0.5/1)], except that they were also susceptible to tigecycline (1/2) ( Table 7 ). The only unexpected result is the overall low activity of ceftolozane-tazobactam against those P. aeruginosa isolates. Among the 753 isolates tested, only 24 isolates exhibited an MIC value of cefiderocol ≥8 μg/mL, among which 45% were NDM producers (n = 11), 30% were OXA-23-producing A. baumannii (n = 7), and two VEB-, one SHV-, one VIM-, and one OXA-48-like producers among K. pneumoniae, P. aeruginosa, and Enterobacter sp. Noteworthy, cefiderocol was active against 68 out of 79 NDM producers, while most of the NDM producers co-produced other β-lactam resistance mechanisms, such as ESBLs (mostly CTX-M-15), porin defect, plasmid-mediated cephalosporinases, and other carbapenemases (data not shown). Cefiderocol was more active (MIC 90 2-4 mg/L) than the comparators (MIC 90 >4 to >64 mg/ L) (cephalosporins, carbapenem, fluoroquinolone, and monobactam) against all the tested strains. The only comparators with equal activity were colistin and tigecycline, with the limitation that tigecycline was not active against P. aeruginosa. Finally, it should be emphasized that cefiderocol displays much favorable pharmacokinetic parameters (tissue diffusion and use in renal impairment) than colistin and tigecycline [19] , which will be an important factor for choosing adequate therapy of infections due to multidrug infections.
